Aeras and its own research partners.

Two of those are in the Phase II proof concept stage and can enroll infants in South Africa, Kenya, Uganda and Mozambique.. Aeras receives grant to develop new vaccines for TB TB vaccine development receives a boostThe Aeras Global TB Vaccine Base is pleased to announce that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional -11.7 million over four years to further its efforts to develop new vaccines to help fight the global epidemic of tuberculosis.As reported in The New England Journal of Medicine, the randomized trial including 1088 patients demonstrated that among those that received abiraterone acetate 1000 mg plus prednisone 5 mg twice-daily, the median radiographic progression-free survival was 16.5 months compared with 8.3 months among those who received placebo plus prednisone. Over a median follow-up period of 22.2 months, a larger proportion of deaths occurred among individuals on prednisone alone than among those that had abiraterone added, at 186 of 542 individuals versus 147 of 546, respectively.